Profile data is unavailable for this security.
About the company
ECO Animal Health Group plc is a United Kingdom-based animal health biotechnology company. The Company is engaged in the manufacturing and supplying of animal health products globally. The Company is focused on providing solutions to respiratory and enteric diseases in pigs and poultry. It provides quality products for swine and poultry, primarily anti-infectives. The Company’s segment includes the United Kingdom, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World. The Company research, develops and commercializes products for livestock. The Company’s lead product, Aivlosin, is an antimicrobial which is used under veterinary prescription for the treatment of economically important respiratory and gastrointestinal diseases in pigs and poultry. The Company is also engaged in researching and developing new solutions to enhance the lives of pigs and poultry.
- Revenue in GBP (TTM)88.46m
- Net income in GBP-1.62m
- Incorporated1984
- Employees228.00
- LocationECO Animal Health Group PLC78 Coombe RoadNEW MALDEN KT3 4QSUnited KingdomGBR
- Phone+44 208 336 2900
- Fax+44 208 336 0909
- Websitehttps://www.ecoanimalhealthgroupplc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redx Pharma PLC | 4.20m | -33.16m | 38.90m | 101.00 | -- | 9.98 | -- | 9.26 | -0.099 | -0.099 | 0.0126 | 0.01 | 0.0954 | -- | 135.55 | 41,603.96 | -75.26 | -52.99 | -166.19 | -88.10 | -- | -- | -789.05 | -206.66 | -- | -- | 0.8405 | -- | -77.52 | 100.71 | -84.15 | -- | 8.12 | -- |
| Arecor Therapeutics PLC | 3.38m | -9.42m | 41.81m | 51.00 | -- | 3.16 | -- | 12.37 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
| Venture Life Group PLC | 51.41m | 921.00k | 53.45m | 165.00 | 79.27 | 0.7009 | 6.61 | 1.04 | 0.0053 | 0.0053 | 0.3847 | 0.6028 | 0.42 | 2.80 | 3.15 | 311,575.80 | 0.7525 | 1.58 | 0.9274 | 1.83 | 39.19 | 40.14 | 1.79 | 3.99 | 0.7355 | 2.12 | 0.2424 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
| e-Therapeutics plc | 475.00k | -8.27m | 56.10m | 38.00 | -- | 1.69 | -- | 118.10 | -0.0154 | -0.0154 | 0.0009 | 0.0568 | 0.0148 | -- | 1.92 | 12,500.00 | -25.79 | -33.25 | -27.10 | -35.11 | 100.00 | 100.00 | -1,741.90 | -1,490.90 | -- | -- | 0.0089 | -- | -0.4193 | -- | -2.53 | -- | 24.22 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.89m | 58.00m | 12.00 | -- | 3.50 | -- | -- | -0.0098 | -0.0098 | 0.00 | 0.0331 | 0.00 | -- | -- | 0.00 | -25.02 | -- | -25.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.60 | -- | -- | -- |
| Celadon Pharmaceuticals PLC | 20.74k | -8.06m | 67.42m | -- | -- | 21.51 | -- | 3,250.69 | -0.1306 | -0.1306 | 0.0003 | 0.0488 | 0.0016 | 267.85 | 0.0248 | -- | -64.68 | -- | -71.16 | -- | -29,080.42 | -- | -40,384.18 | -- | 1.84 | -12.45 | 0.6052 | -- | -- | -- | -- | -- | -- | -- |
| Eco Animal Health Group Plc | 88.46m | -1.62m | 69.44m | 228.00 | -- | 0.8515 | 28.81 | 0.785 | -0.024 | -0.024 | 1.31 | 1.20 | 0.7664 | 1.92 | 3.41 | 387,986.80 | -0.1949 | 6.03 | -0.2645 | 8.02 | 43.05 | 46.41 | -0.2544 | 7.89 | 2.26 | 1.22 | 0.0437 | 55.72 | 3.79 | 4.89 | 246.94 | -35.90 | -4.43 | -- |
| Scancell Holdings Plc | 0.00 | -11.32m | 89.09m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.53m | 91.70m | 34.00 | -- | -- | -- | -- | -0.4068 | -0.4068 | 0.00 | -0.189 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management Ltd.as of 04 Apr 2024 | 11.57m | 17.08% |
| SFM UK Management LLPas of 31 May 2023 | 7.72m | 11.39% |
| AXA Investment Managers UK Ltd.as of 31 May 2023 | 5.20m | 7.67% |
| Lombard Odier Asset Management (Europe) Ltd.as of 31 May 2023 | 3.55m | 5.23% |
| FIL Investment Advisors (UK) Ltd.as of 04 Jan 2024 | 3.42m | 5.05% |
| Canaccord Genuity Wealth Ltd.as of 24 Aug 2022 | 3.38m | 5.00% |
| Chelverton Asset Management Ltd.as of 05 Jan 2024 | 3.25m | 4.79% |
| Amati Global Investors Ltd.as of 30 Jun 2022 | 3.19m | 4.71% |
| Invesco Asset Management Ltd.as of 30 Jun 2022 | 2.29m | 3.39% |
| abrdn Investment Management Ltd.as of 31 May 2023 | 2.05m | 3.03% |
